ABSTRACT
The IDX17119 is a phosphonomidate-based pan-genotypic non-nucleoside inhibitor of Hepatitis C Virus (HCV) NS5B RdRp thumb-II domain. IDX17119 exhibits significant antiviral activity against HCV genotype (GT) 1a, 2a, 3a and 4a. The molecular docking analysis was performed to understand the binding and intermolecular interactions of the IDX17119 molecule at the thumb-II domain of 1a, 2a, 3a and 4a GT NS5B RdRps. The molecular dynamics simulation has been performed to determine the stability of the ligand–protein complexes. We found GT 1a complex is relatively stable compared with other drug-receptor complexes. The binding free energy calculations and free energy decomposition analysis were carried out for all the complexes, the result revealed that the increase in the unfavourable polar contribution affects the binding of IDX17119 with GT 2a NS5B RdRp compared with all other complexes. In addition to this, the effect of mutation at M423 site (M423T/V) alters the conformation and activity of the IDX17119 molecule.
Acknowledgements
The authors thank the Computer Centre, Periyar University, Salem for performing the computational work in the High Performance Cluster (HPC) Computing facility funded by RUSA.
Disclosure statement
No potential conflict of interest was reported by the author(s).